MEdPACTO

Will discuss the joint development of its new pipeline for bone disease treatment with global pharmaceutical companies

MedPacto (CEO Seong-jin Kim), a genome-based drug discovery and a clinical-stage biotechnology company, announced on the 14th that they are participating in the '2023 Bio-Europe Spring' that will be held in Basel, Switzerland March 20th-22nd, 2023.

'BIO-Europe Spring', one of the largest biotech conferences in Europe, attracts a wide range of business leaders including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, and investors from all over the world. Global pharmaceutical companies such as Pfizer, MSD, Novartis, Sanofi, Roche, etc. are attending the event.

Following the JP Morgan Healthcare Conference held in San Francisco last January, MedPacto will discuss the joint development of its new pipelines, such as bone disease treatments, and out-licensing deals with global pharmaceutical companies at the 2023 BIO-Europe Spring.

'Following the JP Morgan event in January, we will have partnering meetings with global pharmaceutical companies and discuss out-licensing opportunities and joint development of our new pipelines.’ stated a MedPacto representative.